Found: 13
Select item for more details and to access through your institution.
Persistence of monoclonal B‐cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus‐associated lymphoproliferative disorders.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 2, p. 237, doi. 10.1111/bjh.19002
- By:
- Publication type:
- Article
NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 4, p. 597, doi. 10.1111/bjh.14843
- By:
- Publication type:
- Article
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
- Published in:
- Annals of Hematology, 2014, v. 93, n. 10, p. 1765, doi. 10.1007/s00277-014-2117-x
- By:
- Publication type:
- Article
Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond.
- Published in:
- Cancers, 2022, v. 14, n. 12, p. 2997, doi. 10.3390/cancers14122997
- By:
- Publication type:
- Article
An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.
- Published in:
- Cancers, 2020, v. 12, n. 4, p. 894, doi. 10.3390/cancers12040894
- By:
- Publication type:
- Article
COVID‐19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 3, p. 559, doi. 10.1002/hon.3121
- By:
- Publication type:
- Article
Elastin MIcrofibriL INterfacer1 (EMILIN‐1) is an alternative prosurvival VLA‐4 ligand in chronic lymphocytic leukemia.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 181, doi. 10.1002/hon.2947
- By:
- Publication type:
- Article
COVID‐19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 712, doi. 10.1002/hon.2916
- By:
- Publication type:
- Article
Integrin Signaling Shaping BTK-Inhibitor Resistance.
- Published in:
- Cells (2073-4409), 2022, v. 11, n. 14, p. N.PAG, doi. 10.3390/cells11142235
- By:
- Publication type:
- Article
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
- Published in:
- Journal of Hematology & Oncology, 2013, v. 6, n. 1, p. 3, doi. 10.1186/1756-8722-6-83
- By:
- Publication type:
- Article
ARHGDIA, a mutant TP53-associated Rho GDP dissociation inhibitor, is over-expressed in gene expression profiles of TP53 disrupted chronic lymphocytic leukaemia cells.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 4, p. 596, doi. 10.1111/bjh.12258
- By:
- Publication type:
- Article
Clinical significance of c.7544-7545 del CT NOTCH1 mutation in chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2013, v. 160, n. 3, p. 415, doi. 10.1111/bjh.12128
- By:
- Publication type:
- Article
Measurable residual disease in chronic lymphocytic leukemia.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1112616
- By:
- Publication type:
- Article